Coronavirus | AMU medical team pulls out all stops for vaccine trial
Updated:
Updated:
January 23, 2021 20:01 IST
Fighting myths and the virus, the university’s JNMCH team completed phase 3 trials for Covaxin, earning praise from the pharma major
Share Article
AAA
Covaxin vaccine immunisation for COVID-19 at Rajiv Gandhi Government General Hospital, in Chennai. File
| Photo Credit:
R. Ragu
Fighting myths and the virus, the university’s JNMCH team completed phase 3 trials for Covaxin, earning praise from the pharma major
Shafiq-ur Rehman Khan is elated as the Jawaharlal Nehru Medical College and Hospital (JNMCH) of Aligarh Muslim University has received a letter of appreciation from Bharat Biotech for completing the enrolment and evaluation process of 1,000 volunteers under phase 3 trials of Covaxin well within time. Mr. Khan, a microbiology postgraduate, was one of the two field officers in the drive.
The biggest criticism against Covaxin was that none of its data was in the public domain when it was given emergency-use authorisation. Sources said Bharat Biotech is hoping to counter the critics with the Lancet piece.
Terming it as international validation of Indian innovation , Ella tweeted: Extremely proud to announce Phase 1 clinical trial studies of Covaxin published in the most prestigious medical journal of The Lancet Infectious Diseases.
Ella also said that 13,000 volunteers (out of 25,800) have been successfully administered the second dose of Covaxin in Phase 3 trials.
Lancet said all adverse events observed in the Phase 1 trials were mild or moderate and were more frequent after the first dose than the second. No significant differences were observed between the vaccinated and control groups, it added.
Covid-19 Vaccine: Bharat Biotech s Covaxin led to enhanced immune responses, says British medical journal Lancet dgtl anandabazar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from anandabazar.com Daily Mail and Mail on Sunday newspapers.